Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
CIA-Linked Investor Helped Quantum Systems Expand in US 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
OpenAI Rejects Apple Trade Secret Theft Claims 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Shein Shares Slide 9% in Hong Kong IPO Debut 
GM Canada Workers Approve C$1.1 Billion Investment Deal 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Add as a preferred source on Google
SAN MATEO, Calif., March 12, 2018 -- Adherium (ASX:ADR), a digital health company that improves medication adherence and patient outcomes, today announced that members of its Board of Directors recently purchased approximately 1.4 million shares on the open market. The timing of these purchases complied with the Company’s “blackout period” policy that required directors and employees to wait seven days following public disclosure of Adherium’s first half 2018 financial results.
“I’m delighted to see this level of support from our Board members. Their personal investment at this time demonstrates a commitment to the Company, as well as confidence in our strategy,” said Arik Anderson, CEO. “We had a great start to fiscal 2018, with first half results that included a 92% increase in revenue and a 63% increase in delivered devices over the comparable period in 2017, demonstrating the meaningful traction we are gaining.”
About Adherium
Adherium is a provider of digital health solutions and a global leader in connected respiratory medical devices. The Company develops, manufactures and supplies patients, pharmaceutical companies, healthcare providers and contract research organizations with the broadest range of connected medical devices for respiratory medications to address sub-optimal medication use and improve health outcomes in chronic disease. Adherium is headquartered in the USA, and operates globally from bases in the USA, Europe and Australasia. Learn more at adherium.com.
Inquiries
Vik Panda, Adherium
Email: [email protected]
Media
Chris Gale, Greentarget
Phone: 646.695.2883
Email: [email protected]
Investors
Leigh Salvo, Gilmartin Group
Phone: 415.937.5404
Email: [email protected]
